Importantly, future studies of newer agents such as antibody drug conjugates and bispecific T-cell engagers targeting DLL3 as well as inhibitors of EHZ2 or PARP should evaluate the intracranial efficacy to finally address the unmet need in SCLC patients with brain metastases. This evidence concerns the gene DLL3 and small cell lung carcinoma.